Medscape Europe: Why France Is Leading on Tick-Borne Diseases

Public health agencies across the globe are blindly following what has been deceitfully established here in the US...

----- Forwarded Message -----
From: CARL TUTTLE <runagain@comcast.net>
To: alice.raffetin@chiv.fr <alice.raffetin@chiv.fr>
Cc: pierre.gilbert@chicreteil.fr <pierre.gilbert@chicreteil.fr>; DFlapan@Medscape.net <dflapan@medscape.net>; eic@medscape.net <eic@medscape.net>; c.perronne@aphp.fr <c.perronne@aphp.fr>
Sent: Tuesday, July 21, 2026 at 08:55:23 AM EDT
Subject: Medscape Europe; Why France Is Leading on Tick-Borne Diseases

Medscape Europe

Why France Is Leading on Tick-Borne Diseases
https://www.medscape.com/viewarticle/why-france-leading-tick-borne-diseases-2026a1000obr 

Excerpt:

In addition to this increased awareness, significant funds have been allocated for research and will enable two dedicated cohorts to be established by early 2027.

Indeed, the first, PIQTIQ, will recruit approximately 4000 people as soon as a tick bite occurs. This cohort will enable us to better understand the natural history following a bite, the incubation period and onset of symptoms, risk factors for the onset of the disease, as well as risk factors for a prolonged course following treatment, using innovative analytical techniques in genetics, immunology, microbiome analysis, host-pathogen interaction, and more. These data will therefore enable us to better describe the natural history of Lyme disease and other tick-borne diseases and to identify the risk factors associated with these diseases. The second Post-Lyme Outcomes Cohort will include 2200 patients in the acute stage of Lyme disease to better understand why some develop PTLDS through clinical, microbiological, genetic, immunological, sociopsychological, microbiome, and sociodemographic data. We will establish a biobank that will help answer current scientific questions about the mechanisms underlying the onset of PTLDS, as well as future questions. These two studies, led by ANRS Emerging Infectious Diseases, will recruit participants over a 2-year period with a 5-year follow-up. They will also enable the collection of data on other tick-borne diseases, even though we know that, epidemiologically speaking, they are rare.

The Intercommunal Hospital Center of Villeneuve-Saint-Georges
40 Allée de la Source
94195 Villeneuve-Saint-Georges Cedex
Attn: Alice Raffetin, MD

 
Dear Dr. Raffetin,

I would like to call attention to the following publication reporting three cases of Acrodermatitis Chronica Atrophicans in Pennsylvania, United States. As you know, ACA is a late-stage cutaneous manifestation of Lyme disease typically found in Europe.

Acrodermatitis Chronica Atrophicans in the USA
https://www.sciencedirect.com/science/article/pii/S2352512625007374

Excerpt:

Notably, 3 patients experienced relapse upon cessation of antibiotic therapy, necessitating prolonged or repeated treatment courses extending up to 3 years.

__________________
Re: Late-stage Lyme disease... At the time of publication, Dr. Ying Zhang was a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health.

Standard antibiotic treatment for Lyme disease does not kill persistent Borrelia bacteria.
http://droopyyoupi.blogspot.com/2015/08/standart-antibiotic-treatment-for-lyme.html

Excerpt:

-What has tuberculosis and Borrelia burgdorferi in common? In the late stage of the disease occurs persistent (tolerant) bacteria, which essentially means that the bacteria lasts and lasts and lasts. They protect themselves against antibiotics and are difficult to treat.

- Both Borrelia burgdorferi and tuberculosis is relatively easy to cure in the early stages, even with the use of one antibiotic. In the late stage it is impossible to cure the disease with the same type of treatment in the acute phase, said Dr. Ying Zhang when he visited the year NorVect conference.

-Dr. Ying Zhang is a professor at the Department of Molecular Microbiology and Immunology at the Johns Hopkins Bloomberg School of Public Health

-Two days after, NorVect conference published Dr. Ying Zhang's latest research Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.

A Drug Combination Screen Identifies Drugs Active against Amoxicillin-Induced Round Bodies of In Vitro Borrelia burgdorferi Persisters from an FDA Drug Library

Jie Feng 1, Wanliang Shi 1, Shuo Zhang 1, David Sullivan 1, Paul G Auwaerter 2, Ying Zhang 1

https://pubmed.ncbi.nlm.nih.gov/27242757/

Abstract

Under experimental stress conditions such as starvation or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which are a type of persister bacteria that appear resistant in vitro to customary first-line antibiotics for Lyme disease. To identify more effective drugs with activity against the round body form of B. burgdorferi, we established a round body persister model induced by exposure to amoxicillin (50 μg/ml) and then screened the Food and Drug Administration drug library consisting of 1581 drug compounds and also 22 drug combinations using the SYBR Green I/propidium iodide viability assay. We identified 23 drug candidates that have higher activity against the round bodies of B. burgdorferi than either amoxicillin or doxycycline. 

_________________

In 1991 the Lyme disease organism, Borrelia burgdorferi, was grown from the cerebrospinal fluid of Dr. Kenneth Liegner’s Lyme patient Vicki Logan at the Centers for Disease Control in Fort Collins, Colorado despite prior treatment with intravenous antibiotics. Here is a copy of Logan’s CDC positive culture report for your review. (Personal Dropbox storage area)
 
(Vicki Logan’s Chronic Lyme Autopsy results Page #1, 2, 3, 4, 5, 6, 7)
 
The destructive nature of Borrelia is evident in the patient’s liver (nutmeg liver), kidneys, heart, lungs and brain. The patient died after the insurer refused additional IV antibiotic therapy.

Our public health officials at the CDC knew early on that we were dealing with an antibiotic resistant/tolerant seronegative disease but suppressed these findings. 

There are 700 peer-reviewed publications referencing persistent infection and in a 2018 study all patients were culture positive even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics.

Persistent Borrelia Infection in Patients with Ongoing Symptoms of Lyme Disease
https://www.mdpi.com/2227-9032/6/2/33

 
Thirty-six years ago Dr. Allen Steere identified chronic Lyme disease which should have set off a red flag prompting an immediate search for better antimicrobials but then did a 180° as he became principal investigator (PI) of the Phase 3 clinical trial for the first Lyme disease vaccine. So all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. Apparently, a chronic relapsing seronegative disease did not fit the business model of patent royalties, vaccine development and pharmaceutical profits.
 
“Chronic neurologic manifestations of Lyme disease” Dr. Allen Steere 1990

Dr. Raffetin,

Focusing on the acute stage of Lyme disease as you are doing in France perpetuates the denial of the late-stage chronic Lyme epidemic leaving hundreds of thousands if not millions worldwide in a debilitated state. Public health agencies across the globe are blindly following what has been deceitfully established here in the US.

Respectfully Submitted,

Carl Tuttle
Independent Researcher
Hudson, NH

"Suppressing evidence of persistent infection after antibiotic treatment for Lyme disease is not collaboration, it is collusion."  -Carl Tuttle 

Question to Google’s Gemini AI:

1. Does a chronic relapsing seronegative disease fit the vaccine model?

AI Response:

A chronic, relapsing, seronegative disease does not fit the traditional vaccine model, which is primarily designed to prevent initial infections. The characteristics you describe present significant scientific and commercial challenges for vaccine developers.

2. Since you agreed that a chronic, relapsing, seronegative disease does not fit the traditional vaccine model this in and of itself would be the motivation to conceal any and all evidence of persistent infection wouldn't you agree? This so-called debate is not a debate at all and deserves a criminal investigation. Who would be a suitable candidate to approach for a legal case?

AI Response:

Allegations of medical fraud are typically handled as civil matters, but they can become criminal if there is evidence of gross negligence, recklessness, or intent to deceive, especially for financial gain.